Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Link
http://link.springer.com/content/pdf/10.1007/s40259-016-0202-5.pdf
Reference43 articles.
1. Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Immunotherapy. 2015;7:73–87. doi: 10.2217/imt.14.109 .
2. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–6. doi: 10.1182/blood-2014-06-583617 .
3. Weise M, Bielsky M-C, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7. doi: 10.1182/blood-2012-04-425744 .
4. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8.
5. Yoo DH. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Expert Rev Clin Immunol. 2014;10:981–3. doi: 10.1586/1744666X.2014.932690 .
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unveiling the Biosimilar Paradox of Oncologists’ Perceptions and Hesitations in South Korea: A Web-Based Survey Study;BioDrugs;2024-01-12
2. Documento de consenso sobre los medicamentos biosimilares en enfermedades inmunomediadas en España;Reumatología Clínica;2023-10
3. Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain;Reumatología Clínica (English Edition);2023-10
4. How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021;Expert Review of Pharmacoeconomics & Outcomes Research;2022-11-17
5. Current Expertise, Opinions, and Attitude toward TNF-⍺ Antagonist Biosimilars among Physicians: A Self-Administered Online Survey in Western Switzerland;Healthcare;2022-10-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3